KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNTech SE (BNTX) EBIT Margin: 2018-2025

Historic EBIT Margin for BioNTech SE (BNTX) over the last 7 years, with Sep 2025 value amounting to 1.67%.

  • BioNTech SE's EBIT Margin fell 286.00% to 1.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.31%, marking a year-over-year increase of 259.00%. This contributed to the annual value of -47.77% for FY2024, which is 6585.00% down from last year.
  • Latest data reveals that BioNTech SE reported EBIT Margin of 1.67% as of Q3 2025, which was down 94.44% from 29.98% recorded in Q2 2025.
  • BioNTech SE's 5-year EBIT Margin high stood at 33.70% for Q1 2025, and its period low was 0.27% during Q4 2023.
  • For the 3-year period, BioNTech SE's EBIT Margin averaged around 11.53%, with its median value being 4.52% (2024).
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by 27,265bps in 2021, then spiked by 1,861bps in 2025.
  • BioNTech SE's EBIT Margin (Quarterly) stood at 4.30% in 2021, then spiked by 88bps to 5.18% in 2022, then tumbled by 491bps to 0.27% in 2023, then spiked by 289bps to 3.16% in 2024, then slumped by 286bps to 1.67% in 2025.
  • Its last three reported values are 1.67% in Q3 2025, 29.98% for Q2 2025, and 33.70% during Q1 2025.